Sabby Management’s Lipocine LPCN Stock Holding History

Sabby Management’s Portfolio LPCN Stock Details LPCN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-9	Closed	-$21K	–	134
2020 Q3	$21K	Buy	9 +3	+50%	+$80	﹤0.01%	129
2020 Q2	$13K	Buy	+6	New	+$78	﹤0.01%	100

Other funds holding LPCN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

KAS

Kestra Advisory Services Austin, Texas $26.4B AUM 21.05% 1-Year Est. Return

Mercer Global Advisors Denver, Colorado $67.6B AUM 18.3% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Aristides Capital Louisville, Kentucky $462M AUM 28.94% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Sabby Management's LPCN Position: Q4 2020 in Review

Sabby Management sold out of Lipocine (LPCN) in Q4 2020, closing a stake of 26,086 shares — an estimated $625K sold.

Sabby Management first reported a position in LPCN in Q2 2014 and held it in 9 quarters. The position peaked at $6.22M in Q2 2015. 33 funds tracked by Wall St. Rank hold LPCN as of Q4 2020.

Sabby Management reported no remaining Lipocine position as of Q4 2020 after selling out during the quarter.
Sabby Management sold 26,086 Lipocine shares in Q4 2020, an estimated $625K.
Sabby Management first reported a position in Lipocine in Q2 2014 and held it in 9 quarters.
Sabby Management's Lipocine position peaked at $6.22M in Q2 2015.
33 funds tracked by Wall St. Rank held Lipocine as of Q4 2020.

Based on Sabby Management's 13F filing for Q4 2020, filed 16 Feb 2021.